Overview

Update
Acquisitions
4 Acquisitions
IPO / Stock
Went Public on Nov 14, 2014 / NASDAQ:JUNO
Headquarters:
Seattle, WA
Description:
Juno Therapeutics, a clinical-stage company, develops immunotherapies for the treatment of cancer.
Founders:
, , , , ,
Categories:
Therapeutics, Health Care, Biotechnology
Website:
http://junotherapeutics.com
Social:

Company Details

Update

Juno is a clinical-stage company that brings together three of the world’s leading cancer centers – Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and Seattle Children’s Research Institute – in unique partnership to advance a broad pipeline of breakthrough immunotherapies. With one of the largest ever Series A investments for a biotech startup, Juno will build on the foundation of novel immunotherapies to develop two distinct and complementary platforms – CARs and TCRs.

Funding Rounds (3) - $310M

Update
DateAmount / RoundValuationLead InvestorInvestors
Aug, 2014$134M / Series B4
Apr, 2014$56M / Series A2
Dec, 2013$120M / Series A2

Acquisitions (4)

Update

Investments (1)

DateInvested InRoundPartner(s)
May, 2015$47M / Venture (Lead)

Current Team (8)

Update

Offices/Locations (1)

Update
  • Office

    307 Westlake Avenue North

    Seattle

    Seattle, WA 98109

    USA

Images (1)

Update

Add Products

Add Sub Organizations

Add Competitors

Add Memberships

Add Customers

Add Partners

Add Videos